ARKOPHARMA BELUX

Wavre ·KBO/BCE: BE 0401.962.852

Loading dossier…

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	nothing on record	not filed	-
31-12-2024	31-07-2025	nothing on record	not filed	-
31-12-2023	31-07-2024	28-11-2025	485 d late	2025-00575153
31-12-2022	31-07-2023	28-11-2023	120 d late	2023-00520591
31-12-2021	31-07-2022	14-04-2023	257 d late	2023-00063087
31-12-2020	31-07-2021	11-08-2021	11 d late	2021-47400521
31-12-2019	31-07-2020	02-07-2020	29 d early	2020-26700232
31-12-2018	31-07-2019	21-06-2019	40 d early	2019-21300470
31-12-2017	31-07-2018	06-07-2018	25 d early	2018-29700530
31-12-2016	31-07-2017	11-07-2017	20 d early	2017-30500582
31-12-2015	31-07-2016	23-08-2016	23 d late	2016-47200304
31-12-2014	31-07-2015	10-07-2015	21 d early	2015-29700369

Metric	This company	Sector median	Position in the sector
Solvency	35.3%	29.7%	better than 56% of 586 sector peers
Net result	€400k	€38k	better than 76% of 585 sector peers
Equity	€1.91M	€481k	better than 68% of 586 sector peers
Staff costs	€2.00M	€506k	higher than 76% of 441 sector peers
Employees (FTE)	21.8	7.5	better than 71% of 388 sector peers

Line item	Code	2023
Balance sheet, Assets
TOTAL ASSETS	20/58	€5.41M
Fixed assets	21/28	€978k
Tangible fixed assets	22/27	€978k
Financial fixed assets	28	€0
Current assets	29/58	€4.43M
Stocks & contracts in progress	3	€2.63M
Amounts receivable within one year	40/41	€1.64M
Cash & bank	54/58	€87k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€5.41M
Equity	10/15	€1.91M
Contributions / capital	10/11	€125k
Reserves	13	€246k
Accumulated profits (losses)	14	€1.54M
Provisions & deferred taxes	16	€83k
Amounts payable	17/49	€3.42M
Amounts payable after one year	17	€50k
Amounts payable within one year	42/48	€3.36M
Trade debts payable within one year	44	€2.51M
Income statement
Turnover	70	€8.52M
Operating result	9901	€568k
Financial income	75	€146
Financial charges	65	€100k
Result before taxes	9903	€468k
Income taxes	67/77	€73k
Net result for the period	9904	€400k
Result to be appropriated	9905	€414k

Summary

Statutory auditor	IRE/IBR number	Tenure
Baudouin Theunissen Commissaire succeeded by Mazars Réviseurs d'Entreprises in 2019	-	13-02-2017 → 10-09-2019
Mazars Réviseurs d'Entreprises Commissaire	-	10-09-2019 → 10-09-2019
Serge Octave Commissaire succeeded by Mazars Réviseurs d'Entreprises in 2019	-	13-02-2017 → 10-09-2019

NACE primary	Groothandel in farmaceutische en medische artikelen(46460)
Legal form	Public limited company(014)
Incorporation	23-12-1943
Status	Active
Postal code	1300